Zynerba stock rises as CBD gel improves rare disorder symptoms; autism program deferred

/
/

Zynerba Pharmaceuticals (ZYNE) stock rose ~8% premarket June 22 after the company said its transdermal CBD gel Zygel help improve behavior¬†…

  • Facebook
  • Twitter
  • Google+
  • Linkedin
  • Pinterest
This div height required for enabling the sticky sidebar